Dow spells out its UF strategy

General manager Ian Barbour spells out Dow’s strategy in the UF membrane market. He thinks it is going to be bigger than reverse osmosis.

As GE contemplates entering Dow’s core reverse osmosis (RO) membrane market, Dow is preparing to meet GE head on in the ultrafiltration (UF) membrane market. The collision reflects the fact that UF membrane treatment looks set to become a multi-billion dollar growth market over the next decade.

Dow bought Chinese UF membrane company Zhejiang Omex in August, and announced ...

Subscription required

To read this full article you must be subscribed to Global Water Intelligence.
Subscribe Now, Sign up for a Free Trial or Log In